Literature DB >> 16344479

Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

Shengjun Chang1, Tian ran Ma, R Dennis Miranda, Maureen E Balestra, Robert W Mahley, Yadong Huang.   

Abstract

Apolipoprotein (apo) E4, a 299-aa protein and a major risk factor for Alzheimer's disease, can be cleaved to generate C-terminal-truncated fragments that cause neurotoxicity in vitro and neurodegeneration and behavioral deficits in transgenic mice. To investigate this neurotoxicity, we expressed apoE4 with C- or N-terminal truncations or mutations in transfected Neuro-2a cells. ApoE4 (1-272) was neurotoxic, but full-length apoE4(1-299) and apoE4(1-240) were not, suggesting that the lipid-binding region (amino acids 241-272) mediates the neurotoxicity and that amino acids 273-299 are protective. A quadruple mutation in the lipid-binding region (I250A, F257A, W264R, and V269A) abolished the neurotoxicity of apoE4(1-272), and single mutations in the region of amino acids 273-299 (L279Q, K282A, or Q284A) made full-length apoE4 neurotoxic. Immunofluorescence staining showed that apoE4(1-272) formed filamentous inclusions containing phosphorylated tau in some cells and interacted with mitochondria in others, leading to mitochondrial dysfunction as determined by MitoTracker staining and flow cytometry. ApoE4(241-272) did not cause mitochondrial dysfunction or neurotoxicity, suggesting that the lipid-binding region alone is insufficient for neurotoxicity. Truncation of N-terminal sequences (amino acids 1-170) containing the receptor-binding region (amino acids 135-150) and triple mutations within that region (R142A, K146A, and R147A) abolished the mitochondrial interaction and neurotoxicity of apoE4(1-272). Further analysis showed that the receptor-binding region is required for escape from the secretory pathway and that the lipid-binding region mediates mitochondrial interaction. Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344479      PMCID: PMC1311737          DOI: 10.1073/pnas.0508254102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  70 in total

1.  Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes.

Authors:  J F Diedrich; H Minnigan; R I Carp; J N Whitaker; R Race; W Frey; A T Haase
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.

Authors:  M Green; P M Loewenstein
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

3.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

4.  Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction.

Authors:  M V Berridge; A S Tan
Journal:  Arch Biochem Biophys       Date:  1993-06       Impact factor: 4.013

Review 5.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

6.  Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.

Authors:  Walter J Brecht; Faith M Harris; Shengjun Chang; Ina Tesseur; Gui-Qiu Yu; Qin Xu; Jo Dee Fish; Tony Wyss-Coray; Manuel Buttini; Lennart Mucke; Robert W Mahley; Yadong Huang
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

Review 7.  Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease.

Authors:  Yadong Huang; Karl H Weisgraber; Lennart Mucke; Robert W Mahley
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Mitochondrial ALDH2 deficiency as an oxidative stress.

Authors:  Shigeo Ohta; Ikuroh Ohsawa; Kouzin Kamino; Fujiko Ando; Hiroshi Shimokata
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

10.  Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia.

Authors:  U Beisiegel; W J Schneider; J L Goldstein; R G Anderson; M S Brown
Journal:  J Biol Chem       Date:  1981-11-25       Impact factor: 5.157

View more
  133 in total

Review 1.  An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease.

Authors:  Allen D Roses
Journal:  Arch Neurol       Date:  2010-05

2.  Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.

Authors:  Haim Belinson; Zehavit Kariv-Inbal; Rakez Kayed; Eliezer Masliah; Daniel M Michaelson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 3.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Genetic variation at a single locus and age of onset for Alzheimer's disease.

Authors:  Michael W Lutz; Donna G Crenshaw; Ann M Saunders; Allen D Roses
Journal:  Alzheimers Dement       Date:  2010-03       Impact factor: 21.566

5.  Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.

Authors:  Jens Brodbeck; Maureen E Balestra; Ann M Saunders; Allen D Roses; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

6.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

Authors:  P Hemachandra Reddy; M Flint Beal
Journal:  Trends Mol Med       Date:  2008-01-22       Impact factor: 11.951

Review 7.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice.

Authors:  Rachel E Bennett; Thomas J Esparza; Hal A Lewis; Eddie Kim; Christine L Mac Donald; Patrick M Sullivan; David L Brody
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

10.  GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice.

Authors:  Gang Li; Nga Bien-Ly; Yaisa Andrews-Zwilling; Qin Xu; Aubrey Bernardo; Karen Ring; Brian Halabisky; Changhui Deng; Robert W Mahley; Yadong Huang
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.